Public market insider net buying at Acasti Pharma (ACST)

Public market insider net buying at Acasti Pharma (V:ACST)

Richard Paul Schottenfeld, a 10% Holder, acquired 295,340 Common Shares (Actions de catégorie A) on an indirect ownership basis for registered holder Koyote Capital Group LLC at prices ranging from US$1.012 to US$1.416 between October 4th to 5th, 2018. The insider also acquired 200,000 Common Shares (Actions de catégorie A) on an indirect ownership basis for registered holder Phase Five Partners at a price of US$1.000 on October 4th, 2018. This represents a $620,502 net investment into the company's shares and an account share holdings change of greater than 100%.

Acasti Pharma is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).